血清神经元烯醇化酶水平对小细胞肺癌预后影响的系统评价_中国循证医学杂志

作者：

汤建华 ¹ , 张志华 ¹ ,  王睿 ² , 唐惠林 ³ , 张桂云 ² , 龙丽艳 ² , 陈良安 ²

1. 河北北方学院附属第一医院（张家口 000750）；2. 解放军总医院循证医学中心（北京 100853）；3. 北京大学第三临床医学院药剂科（北京 100191）;

关键词：

神经元烯醇化酶小细胞肺癌预后系统评价

DOI：

10.7507/1672-2531.20090016

视频：

导出 下载 收藏 扫码 引用

摘要 全文 图表 视频 参考文献 施引文献

目的　评价血清神经元烯醇化酶（NSE）水平对小细胞肺癌患者的预后影响。
方法　计算机检索MEDLINE、EMbase、CBMdisc、Cochrane Central Register of Controlled Trials 等数据库，并从符合纳入标准的文献中查找相关文献。检索时间从1950年到2007年12月。由2 名评价者独立检索、评价文献交叉核对后提取有效数据进行Meta 分析。
结果　共纳入9 个研究共2 021例小细胞肺癌患者。按作者对NSE 水平的截断值，其中66.0%（36.5%～79%）的病例血清NSE 浓度呈现高水平。NSE浓度高水平对患者的危害是NSE 低水平的1.27倍［95%CI（1.19，1.35），P=0.281］。
结论　治疗前NSE浓度高水平患者预后总生存率较NSE低水平患者差，NSE水平对小细胞肺癌预后有一定的预测价值。但由于本研究纳入文献可能存在发表偏倚、选择偏倚、测量偏倚的高度可能性，上述结论应慎重对待。期待更多高质量、同质性的研究来精确评价NSE 的预后价值。

引用本文： 汤建华,张志华,王睿,唐惠林,张桂云,龙丽艳,陈良安. 血清神经元烯醇化酶水平对小细胞肺癌预后影响的系统评价. 中国循证医学杂志, 2009, 09(1): 76-80. doi: 10.7507/1672-2531.20090016 复制

1.	Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin, 2000, 50: 7-33.
2.	Parkin DM, Bray F, Ferlay J, et al. Global Cancer Statistics. CA Cancer J Clin, 2005, 55: 74-108.
3.	Lassen U, Osterlind K, Hansen M, et al. Long-term survival in small-cell lung duration in small cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years. An analysis of 1, 714 consecutive patients. J Clin Oncol, 1995, 13: 1215-1220.
4.	Lassen U, Osterlind K, Hansen M, et al. Long-term survival in smallcell lung cancer: posttreatment characteristics in patients surviving 5 to 18+years. An analysis of 1, 714 consecutive patients. J Clin Oncol, 1995, 13: 1215-1220.
5.	Souhami RL, Bradbury I, Geddes DM, et al. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res, 1985, 45: 2878-2882.
6.	Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res, 1986, 46: 4189-4194.
7.	Ar r i a g ada R, Le Che v a l i e r T, Pi gnon JP, e t al . Ini t i a l chemotherapeutic doses and survival in patients with limited smallcell- lung cancer. N Engl J Med, 1993, 329: 1848-1852.
8.	Deglor igio CM, Got t PS, RobininczAL, e t al . Neuron - specificennlase, a marker of acute neuronal injury is increased in complex partial status epilepticus. Epilepsia, 1996, 37(7): 606.
9.	历为良, 钱桂生, 黄桂君, 等. 人肺癌组织细胞Na/H交换蛋白-1基因的表达与其抗凋亡的关系. 中国癌症杂志, 2000, 10(2): 14.
10.	马兰海. 血清神经元特异性烯醇化酶对小细胞肺癌的诊断价值探讨. 放射免疫学杂志, 2002, 15(6): 351-352.
11.	刘关键, 吴泰相, 康德英. Meta-分析中的统计学过程. 中国临床康复, 2003, 7(4): 538-539.
12.	Johnson PWM, Joel SP, Love S, et al. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer, 1993, 67: 760-766.
13.	JorgensenLGM, Osterlind K, Genolia J, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC) a combined multivariable analysis on data from nine centres. Br J Cancer, 1996, 74: 463-467.
14.	Quoix E, PurohitM A, Beau F, et al. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer, 2000, 30: 127-134.
15.	Shibayama T, Ueoka H, Nishii K, et al. Complementary roles of progastrin- releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer, 2001, 32: 61-69.
16.	金炳文, 赵兰, 周彩存, 等. 神经元特异性烯醇化酶检测在小细胞肺癌预后中的价值. 中华结核和呼吸杂志, 2001, 24(12): 722-724.
17.	Bremnes RM, Sundstrom S, Aasebø U, et al. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer, 2003, 39: 303-313.
18.	Ando S, Suzuki M, Yamamoto N, et al. The prognostic value of both NSE and cyfra21-1 in Small Cell Lung Cancer. Anticancer Res, 2004, 24: 1941-1946.
19.	宋丽华, 宋现让, 张锡芹, 等. 小细胞肺癌患者预后因素分析. 中华肿瘤杂志, 2004, 26(7): 413-416.
20.	刘丽诗, 胡华成. 神经元特异性烯醇化酶、癌胚抗原、乳酸脱氢酶在小细胞肺癌中的预后价值比较. 苏州大学学报(医学版), 2005, 25 (2): 261-264.

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin, 2000, 50: 7-33.
2. Parkin DM, Bray F, Ferlay J, et al. Global Cancer Statistics. CA Cancer J Clin, 2005, 55: 74-108.
3. Lassen U, Osterlind K, Hansen M, et al. Long-term survival in small-cell lung duration in small cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years. An analysis of 1, 714 consecutive patients. J Clin Oncol, 1995, 13: 1215-1220.
4. Lassen U, Osterlind K, Hansen M, et al. Long-term survival in smallcell lung cancer: posttreatment characteristics in patients surviving 5 to 18+years. An analysis of 1, 714 consecutive patients. J Clin Oncol, 1995, 13: 1215-1220.
5. Souhami RL, Bradbury I, Geddes DM, et al. Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res, 1985, 45: 2878-2882.
6. Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res, 1986, 46: 4189-4194.
7. Ar r i a g ada R, Le Che v a l i e r T, Pi gnon JP, e t al . Ini t i a l chemotherapeutic doses and survival in patients with limited smallcell- lung cancer. N Engl J Med, 1993, 329: 1848-1852.
8. Deglor igio CM, Got t PS, RobininczAL, e t al . Neuron - specificennlase, a marker of acute neuronal injury is increased in complex partial status epilepticus. Epilepsia, 1996, 37(7): 606.
9. 历为良, 钱桂生, 黄桂君, 等. 人肺癌组织细胞Na/H交换蛋白-1基因的表达与其抗凋亡的关系. 中国癌症杂志, 2000, 10(2): 14.
10. 马兰海. 血清神经元特异性烯醇化酶对小细胞肺癌的诊断价值探讨. 放射免疫学杂志, 2002, 15(6): 351-352.
11. 刘关键, 吴泰相, 康德英. Meta-分析中的统计学过程. 中国临床康复, 2003, 7(4): 538-539.
12. Johnson PWM, Joel SP, Love S, et al. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer, 1993, 67: 760-766.
13. JorgensenLGM, Osterlind K, Genolia J, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC) a combined multivariable analysis on data from nine centres. Br J Cancer, 1996, 74: 463-467.
14. Quoix E, PurohitM A, Beau F, et al. Comparative prognostic value of lactate dehydrogenase and neuron-specific enolase in small-cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer, 2000, 30: 127-134.
15. Shibayama T, Ueoka H, Nishii K, et al. Complementary roles of progastrin- releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer, 2001, 32: 61-69.
16. 金炳文, 赵兰, 周彩存, 等. 神经元特异性烯醇化酶检测在小细胞肺癌预后中的价值. 中华结核和呼吸杂志, 2001, 24(12): 722-724.
17. Bremnes RM, Sundstrom S, Aasebø U, et al. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer, 2003, 39: 303-313.
18. Ando S, Suzuki M, Yamamoto N, et al. The prognostic value of both NSE and cyfra21-1 in Small Cell Lung Cancer. Anticancer Res, 2004, 24: 1941-1946.
19. 宋丽华, 宋现让, 张锡芹, 等. 小细胞肺癌患者预后因素分析. 中华肿瘤杂志, 2004, 26(7): 413-416.
20. 刘丽诗, 胡华成. 神经元特异性烯醇化酶、癌胚抗原、乳酸脱氢酶在小细胞肺癌中的预后价值比较. 苏州大学学报(医学版), 2005, 25 (2): 261-264.

上一篇
临床病理讨论——咳嗽、咳白痰、双肺阴影
下一篇
12例重症军团菌肺炎回顾性分析

中国循证医学杂志

血清神经元烯醇化酶水平对小细胞肺癌预后影响的系统评价

摘要 全文 图表 视频 参考文献 施引文献

上一篇

下一篇

Format

Content

中国循证医学杂志

血清神经元烯醇化酶水平对小细胞肺癌预后影响的系统评价

摘要 全文 图表 视频 参考文献 施引文献

上一篇

下一篇

Format

Content

摘要全文图表视频参考文献施引文献